Association between A2a receptor gene polymorphisms and caffeine-induced anxiety

Neuropsychopharmacology

Volumn 28, Issue 9, 2003, Pages 1694-1702

  Alsene, Karen ^a,d   Deckert, Jürgen ^b   Sand, Philipp ^c   De Wit, Harriet ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Adenosine A1 receptor; Adenosine A2a receptor; Anxiety; Caffeine; Panic disorder; Polymorphism

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; CAFFEINE; PLACEBO; ADENOSINE RECEPTOR; CENTRAL STIMULANT AGENT; CYSTEINE; THREONINE;

ANXIETY; ARTICLE; DNA POLYMORPHISM; GENOTYPE; HUMAN; MOOD; NORMAL HUMAN; PANIC; PRIORITY JOURNAL; SELF REPORT; ADULT; ANIMAL; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SEQUENCE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; HETEROSIS; MALE; METHODOLOGY; NEUROPSYCHOLOGICAL TEST; PAIN ASSESSMENT; PERSONALITY TEST; TANDEM REPEAT; TIME;

ADULT; ANIMALS; ANXIETY; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CYSTEINE; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HUMANS; HYBRID VIGOR; MALE; NEUROPSYCHOLOGICAL TESTS; PAIN MEASUREMENT; PERSONALITY INVENTORY; POLYMORPHISM, GENETIC; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; SEQUENCE ANALYSIS, DNA; TANDEM REPEAT SEQUENCES; THREONINE; TIME FACTORS; VARIATION (GENETICS);

EID: 0141557733     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300232     Document Type: Article

References (50)

1. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Text Revised. American Psychiatric Association: Washington, DC.
2. Belkhir K, Borsa P, Chiki L, Raufaste N, Bonhomme F (2001). 1996-2001 GENETIX 4.02, logiciel sous Windows TM pour la genetique des populations. Laboratoire Genome, Populations, Interactions, CNRS UMR 5000. Universite de Montpellier II: Montpellier.
3. Boulenger JP, Uhde TW, Wolff EA, Post RM (1984). Increased sensitivity to caffeine in patients with panic disorders. Arch Gen Psychiatry 41: 1067-1071.
4. Brukner I, Jurukovski V, Konstantinovic M, Savic A (1991). Curved DNA without AA/TT dinucleotide step. Nucleic Acids Res 19: 3549-3551.
5. Chait LD (1992). Factors influencing the subjective response to caffeine. Behav. Pharmacol 3: 219-228.
6. Charney DS, Heninger GR, Jallon PI (1985). Increased anxiogenic effects of caffeine in panic disorder. Arch Gen Psychiatry 42: 233-243.
7. Deckert J, Kuhlenbäumer G, Weiß K, Schirmacher A, Ringelstein EB, Arolt V et al (2001). Chromosome 22q11.2 as a candidate gene locus: association of the more active COMT-allele with panic disorder. Am J Med Genet 105: 570.
8. Deckert J, Nothen MM, Albus M, Franzek E, Rietschel M, Ren H et al (1998a). Adenosine A1 receptor and bipolar affective disorder: systematic screening of the gene and association studies. Am J Med Genet 81: 18-23.
9. 2a gene to the development of disease. Mol Psychiatry 3: 81-85.
10. 2aAR) gene: systematic mutation screening in patients with schizophrenia. J Neural Transm 103: 1447-1455.
11. den Dunnen JT, Antonorakis SE (2000). Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 15: 7-12.
12. Durrant KL (2002). Known and hidden sources of caffeine in drug, food, and natural products. J Am Pharm Assoc (Wash.) 42: 625-637.
13. Evans SM, Griffiths RR (1991). Dose-related caffeine discrimination in normal volunteers: individual differences in subjective and self-reported cues. Behav Pharmacol 2: 345-356.
14. Eysenck SBG (1993). The 17: development of a measure of impulsivity and its relationship to personality. In: McCown WG, Johnson JL, Shure MB (eds) The Impulsive Client. American Psychological Association: Washington, DC. pp 141-149.
15. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W (2000). Structure and function of adenosine receptors and their genes. Arch Pharmacol 362: 364-377.
16. Fu L, Ma WL, Benchimol S (1999). A translation repressor element resides in the 3′ untranslated region of human p53 mRNA. Oncogene 18: 6419-6424.
17. Gabrielian A, Pongor S (1996). Correlation of intrinsic DNA curvature with DNA property periodicity. FEBS Lett 393: 65-68.
18. Gilbert RM (1976). Caffeine as a drug of abuse. In: Gibbins RJ, Israel Y, Kalant H, Popham RE, Schmidt W, Smart RG (eds) Research Advances in Alcohol and Drug Problems, Vol. 3 Wiley: New York. pp 49-176.
19. Goldstein A, Kaizer S, Whitby O (1969). Psychotropic effects of caffeine in man. IV. Quantitative and Qualitative differences associated with habituation to coffee. Clin Pharmacol Therap 10: 489-497.
20. Graham DM (1978). Caffeine - its identity, dietary sources, intake and biological effects. Nutr Rev 36: 97-102.
21. Griffiths RR, Mumford GK (1996). Caffeine reinforcement, discrimination, tolerance and physical dependence in laboratory animals and humans. In: Schuster CR, Kuhar MJ (eds). Pharmacological Aspects of Drug Dependence, (Chapter 9) Springer Verlag: Berlin.
22. Griffiths RR, Woodson PP (1988). Reinforcing properties of caffeine: studies in human and laboratory animals. Pharmacol Biochem Behav 29: 419-427.
23. Gupta U (1993). Effects of caffeine on recognition. Pharmacol Biochem Behav 44: 393-396.
24. Gupta U, Dubey GP, Gupta BS (1994). Effects of caffeine on perceptual judgement. Neuropsychobiology 30: 185-188.
25. Hart P, Farrell GC, Cooksley WGE, Powell L (1976). Enhanced drug metabolism in cigarette smokers. Br Med J 2: 147-149.
26. Johansson B, Halldner L, Dunwiddie TV, Masino SA, Poelchen W, Gimenez-Llort L et al (2001). Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci USA 98: 9407-9412.
27. Kamimori GH, Joubert A, Otterstetter R, Santaromana M, Eddington ND (1999). The effects of the menstrual cycle on the pharmacokinetics of caffeine in normal, healthy eumenorrheic females. Eur J Clin Pharmacol 55: 445-449.
28. Kaplan GB, Greenblatt DJ, Ehrenberg BL, Goddard JE, Cotreau NM, Harmatz JS et al (1997). Dose-dependent pharmacokinetics and psychomotor effects of caffeine in humans. J Clin Pharmacol 37: 693-703.
29. Kendler KS, Prescott CA (1999). Caffeine intake, tolerance, and withdrawal in women: A population-based twin study. Am J Psychiatry 156: 223-228.
30. Lader M (1969). Comparison of amphetamine sulphate and caffeine citrate in man. Psychopharmacologia 14: 83-94.
31. Ledent C, Vaugeois JM, Schiffmann SN Pedrazzini T, El Yacoubi M, Vanderhaeghen JJ et al (1997). Aggressiveness, hypoalgesia, and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388: 674-682.
32. Lee MA, Flegel P, Greden JF, Cameron OG (1988). Anxiogenic effects of caffeine on panic and depressed patients. Am J Psychiatry 145: 632-635.
33. Lieberman HR, Wurtman RJ, Emde GG, Roberts C, Coviella ILG (1987). The effects of low doses of caffeine on human performance and mood. Psychopharmacology 92: 308-312.
34. Liguori A, Grass JA, Hughes JR (1999). Subjective effects of caffeine among introverts and extraverts in the morning and evening. Exp Clin Psychopharmacol 7: 244-249.
35. Loke WH (1988). Effects of caffeine on mood and memory. Physiol Behav 44: 367-372.
36. Martin WR, Sloan JW, Sapira JD, Jasinski RM (1971). Physiological, subjective and behavioral tests of amphetamine, methamphetamine, ephedrine, phenmetrazine and methylphenidate in man. Clin Pharmacol Ther 12: 245-258.
37. McNair D, Lorr M, Droppleman DL (1971). Profile of Mood States. Educational and Industrial Testing Service: San Diego.
38. Mumford GK, Evans SM, Kaminski BJ, Preston KL, Sannerud CA, Silverman K et al (1994). Discriminative stimulus and subjective effects of theobromine and caffeine in humans. Psychopharmacology 115: 1-8.
39. Patton JH, Stanford MS, Barratt ES (1995). Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol 51: 768-774.
40. Schuler GD, Altschul SF, Lipman DJ (1991). A workbench for multiple alignment construction and analysis. Proteins 9: 180-190.
41. Scott Jr WH, Coyne KM, Johnson MM, Lausted CG, Sahota M, Johnson AT (2002). Effects of caffeine on performance of low intensity tasks. Percept Motor Skills 94: 521-532.
42. Shacham S (1983). A shortened version of the profile of mood states. J Pers Assess 47: 305-307.
43. Snyder SH, Sklar P (1984). Behavioral and molecular actions of caffeine: Focus on adenosine. J Psychiatry Res 18: 91-106.
44. Song X, Singh SM (2001). Distribution and molecular characterization of mRNA-bending proteins specific to the (U)15 region of 3′UTR of the mouse catalase (Cas-1). DNA Cell Biol 20: 339-348.
45. Svenningsson P, Nomikos GG, Ongini E, Fredholm BB (1997). Antagonism of adenosine A2A receptors underlies the behavioral activating effect of caffeine and is associated with reduced expression of messenger RNA for NGFI-A and NGFI-B in caudate-putamen and nucleus accumbens. Neuroscience 79: 753-764.
46. Svensson E, Persson LO, Sjoberg L (1980). Mood effects of diazepam and caffeine. Psychopharmacology 67: 73-80.
47. Uhde TW, Boulanger JP, Vittone B, Jimerson DC, Post PM (1984). Caffeine: relationship to human anxiety plasma MHPG and cortisol. Psychopharmacol Bull 20: 426-430.
48. Wechsler D (1958). The Measure and Appraisal of Adult Intelligence. Williams and Wilkins: Baltimore.
49. White BC, Lincoln CA, Pearce NW, Reeb R, Vaida C (1980). Anxiety and muscle tension as consequences of caffeine withdrawal. Science 209: 1547-1548.
50. Yamada K, Hattori E, Shimizu M, Sugaya A, Shibuya H, Yoshikawa T (2001). Association studies of the cholecystokinin B receptor and A2a adenosine receptor genes in panic disorder. J Neural Transm 108: 837-848.